Carboplatin alone not adequate for ovarian cancer in frail seniors

The science of sound, vibration to better diagnose, treat brain diseases
27 April 2021
COVID-19 vaccine hesitancy: Understandable and irrational
27 April 2021

Carboplatin alone not adequate for ovarian cancer in frail seniors

(HealthDay)—For vulnerable older patients with ovarian cancer, single-agent carboplatin is less active, with worse survival, than combination carboplatin-paclitaxel regimens, according to a study published online April 22 in JAMA Oncology.

Comments are closed.